08 managementanticoagulanttherapy

294 views

Published on

Published in: Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
294
On SlideShare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
16
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

08 managementanticoagulanttherapy

  1. 1. Evidence-Based Management ofAnticoagulant Therapy-----Antithrombotic Therapy and Preventionof Thrombosis, 9th ed: AmericanCollege of Chest Physicians Evidence-Based Clinical Practice GuidelinesCopyright: American College of Chest Physicians 2012©
  2. 2. IntroductionThis chapter addresses the many general managementquestions related to anticoagulants:- Includes initiation, maintenance, dosing, druginteractions, bleeding, organization of care- Management in pregnancy and for children iscovered in other chaptersSystematic reviews revealed sufficient but usually low-quality evidence to provide suggested guidance for only23 questions- Only two questions (INR therapeutic range 2-3;avoidance of routine pharmacogenetic testing toguide VKA dosing) had sufficient evidence tosupport a strong recommendation.
  3. 3. Loading Dose for Initiation of Vitamin K Antagonist (VKA) TherapyFor patients sufficiently healthy to be treated as outpatients, wesuggest initiating VKA therapy with warfarin 10 mg daily for thefirst 2 days followed by dosing based on international normalizedratio (INR) measurements rather than starting with the estimatedmaintenance dose (Grade 2C).
  4. 4. Initial Dose Selection and Pharmacogenetic TestingFor patients initiating VKA therapy, we recommend against theroutine use of pharmacogenetic testing for guiding doses of VKA(Grade 1B).
  5. 5. Initiation Overlap for Heparin and VKAFor patients with acute VTE, we suggest that VKA therapy bestarted on day 1 or 2 of low-molecular-weight heparin (LMWH) orlow-dose unfractionated heparin (UFH) therapy rather than waitingfor several days to start (Grade 2C).
  6. 6. Monitoring Frequency for VKAsFor patients taking VKA therapy with consistently stable INRs, wesuggest an INR testing frequency of up to 12 weeks rather thanevery 4 weeks (Grade 2B).
  7. 7. Management of the Single Out-of-Range INRFor patients taking VKAs with previously stable therapeutic INRswho present with a single out-of-range INR of 0.5 below or≤above therapeutic, we suggest continuing the current dose andtesting the INR within 1 to 2 weeks (Grade 2C).
  8. 8. Bridging for Low INRsFor patients with stable therapeutic INRs presenting with a singlesubtherapeutic INR value, we suggest against routinelyadministering bridging with heparin (Grade 2C).
  9. 9. Vitamin K SupplementationFor patients taking VKAs, we suggest against routine use ofvitamin K supplementation (Grade 2C).
  10. 10. Anticoagulation Management Services for VKAs(Best Practices Statement) We suggest that health-care providerswho manage oral anticoagulation therapy should do so in asystematic and coordinated fashion, incorporating patienteducation, systematic INR testing, tracking, follow-up, and goodpatient communication of results and dosing decisions.
  11. 11. Patient Self-Testing and Self-ManagementFor patients treated with VKAs who are motivated and candemonstrate competency in self-management strategies, includingthe self-testing equipment, we suggest patient self-managementrather than usual outpatient INR monitoring (Grade 2B). For allother patients, we suggest monitoring that includes the safeguardsin our best practice statement 3.5.
  12. 12. Dosing Decision SupportFor dosing decisions during maintenance VKA therapy, we suggestusing validated decision support tools (paper nomograms orcomputerized dosing programs) rather than no decision support(Grade 2C).Remarks: Inexperienced prescribers may be more likely to improveprescribing with use of decision support tools than experiencedprescribers.
  13. 13. VKA Drug Interactions to AvoidFor patients taking VKAs, we suggest avoiding concomitanttreatment with nonsteroidal antiinflammatory drugs, includingcyclooxygenase-2-selective nonsteroidal antiinflammatory drugs,and certain antibiotics (see Table 8 in main article) (Grade 2C).For patients taking VKAs, we suggest avoiding concomitanttreatment with antiplatelet agents except in situations where benefitis known or is highly likely to be greater than harm from bleeding,such as patients with mechanical valves, patients with acutecoronary syndrome, or patients with recent coronary stents orbypass surgery (Grade 2C).
  14. 14. Optimal Therapeutic INR RangeFor patients treated with VKAs, we recommend a therapeutic INRrange of 2.0 to 3.0 (target INR of 2.5) rather than a lower (INR < 2)or higher (INR 3.0-5.0) range (Grade 1B).
  15. 15. Therapeutic Range for High-Risk GroupsFor patients with antiphospholipid syndrome with previous arterialor venous thromboembolism, we suggest VKA therapy titrated to amoderate-intensity INR range (INR 2.0-3.0) rather than higherintensity (INR 3.0-4.5) (Grade 2B).
  16. 16. Discontinuation of TherapyFor patients eligible to discontinue treatment with VKA, wesuggest abrupt discontinuation rather than gradual tapering of thedose to discontinuation (Grade 2C).
  17. 17. Unfractionated Heparin (UFH) Dose Adjustment by WeightFor patients starting IV UFH, we suggest that the initial bolus andthe initial rate of the continuous infusion be weight adjusted (bolus80 units/kg followed by 18 units/kg per h for VTE; bolus 70units/kg followed by 15 units/kg per h for cardiac or strokepatients) or use of a fixed dose (bolus 5,000 units followed by1,000 units/h) rather than alternative regimens (Grade 2C).
  18. 18. Dose Management of Subcutaneous (SC) UFHFor outpatients with VTE treated with SC UFH, we suggestweight-adjusted dosing (first dose 333 units/kg, then 250 units/kg)without monitoring rather than fixed or weight-adjusted dosingwith monitoring (Grade 2C).
  19. 19. Therapeutic Dose of LMWH in Patients With Decreased Renal FunctionFor patients receiving therapeutic LMWH who have severe renalinsufficiency (calculated creatinine clearance < 30 mL/min), wesuggest a reduction of the dose rather than using standard doses(Grade 2C).
  20. 20. Fondaparinux Dose Management by WeightFor patients with VTE and body weight over 100 kg, we suggestthat the treatment dose of fondaparinux be increased from the usual7.5 mg to 10 mg daily SC (Grade 2C).
  21. 21. Vitamin K for Patients Taking VKAs With High INRs Without Bleeding(a) For patients taking VKAs with INRs between 4.5 and 10 andwith no evidence of bleeding, we suggest against the routine use ofvitamin K (Grade 2B).(b) For patients taking VKAs with INRs > 10.0 and with noevidence of bleeding, we suggest that oral vitamin K beadministered (Grade 2C).
  22. 22. Clinical Prediction Rules for Bleeding While Taking VKAFor patients initiating VKA therapy, we suggest against the routineuse of clinical prediction rules for bleeding as the sole criterion towithhold VKA therapy (Grade 2C).
  23. 23. Treatment of Anticoagulant-Related BleedingFor patients with VKA-associated major bleeding, we suggestrapid reversal of anticoagulation with four-factor prothrombincomplex concentrate rather than with plasma. (Grade 2C).We suggest the additional use of vitamin K 5 to 10 mgadministered by slow IV injection rather than reversal withcoagulation factors alone (Grade 2C).
  24. 24. Endorsing OrganizationsThis guideline has received the endorsement of thefollowing organizations:• American Association for Clinical Chemistry• American College of Clinical Pharmacy• American Society of Health-System Pharmacists• American Society of Hematology• International Society of Thrombosis and Hemostasis
  25. 25. Acknowledgement of SupportThe ACCP appreciates the support of the following organizationsfor some part of the guideline development process:Bayer Schering Pharma AGNational Heart, Lung, and Blood Institute (Grant No.R13 HL104758)With educational grants fromBristol-Myers Squibb and Pfizer, Inc.Canyon Pharmaceuticals, andsanofi-aventis U.S.Although these organizations supported some portion of the developmentof the guidelines, they did not participate in any manner with the scope,panel selection, evidence review, development, manuscript writing,recommendation drafting or grading, voting, or review. Supporters did notsee the guidelines until they were published.

×